Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

everolimus

Known as: SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, 42-O-(2-Hydroxy)ethyl Rapamycin 
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in… Expand
  • table 1
  • table 2
  • table 6
  • table 7
  • table 8
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Tumor genome sequencing reveals the molecular basis of a patient’s unexpected and dramatic response to a cancer drug. Cancer… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
 
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Previous studies have established the superiority of coronary everolimus-eluting stents over paclitaxel-eluting stents… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Everolimus-eluting and paclitaxel-eluting stents, compared with bare metal stents, reduced the risk of restenosis in… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy… Expand
Is this relevant?